Hypertriglyceridemia: A Review of Clinical Relevance and Treatment Options: Focus on Cerivastatin
SUMMARYThe triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD.Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive s...
Saved in:
| Published in | Current medical research and opinion Vol. 17; no. 1; pp. 60 - 73 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Reading
Informa UK Ltd
2001
Taylor & Francis Librapharm Informa Healthcare |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-7995 1473-4877 |
| DOI | 10.1185/0300799039117028 |
Cover
| Abstract | SUMMARYThe triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD.Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive subjects after increased low-density lipoprotein cholesterol (LDL-C), is defined by the National Cholesterol Education Programme (NCEP) as a fasting TG level of >2.26 mmol/l (>200 mg/dl) and is recognised as a primary indicator for treatment in type IIb dyslipidemia. Raised TG levels can be present in individuals at risk for CHD when the total cholesterol is normal. However, not all individuals with raised TG levels have increased risk of CHD. Factors such as: diet, age, lifestyle, and a range of medical conditions, drug therapy and metabolic disorders, can all affect the TG level. In some of these circumstances, other factors protect against the risk of CHD, and can minimise or negate the effect of the risk factors present.Although TG reducing therapy has been shown to be associated with an improved clinical outcome, more research is needed to determine whether this is an independent effect of TG reduction or an effect of normalising the overall lipid profile in hypertriglyceridemic patients. Further trials are required to quantify the clinical benefits of lowering TG to 'target' levels and to confirm targets defined by NCEP-II (shown in Table 1).The role of TG in CHD pathogenesis is thought to involve several direct and indirect mechanisms, such as effects on the metabolism of other lipoproteins, transport proteins, enzymes, and on coagulation and endothelial dysfunction. More research is required to fully elucidate the role of TG, the ways in which it can influence other risk factors and the mechanism of its own more direct role in the atherogenic process.Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. However, recent retrospective real-life clinical studies show that only 38% of patients receiving some form of lipid-lowering therapy achieved NCEP-defined LDL-C target levels, demonstrating the need for the use of more aggressive treatment.In hypertriglyceridemic patients, the newer statins, cerivastatin and atorvastatin, have shown comparable efficacy in reducing TG compared with the older statins. Achieving NCEP target lipid levels has been shown to reduce the risk of cardiovascular disease in dyslipidemic individuals, including high-risk patient groups such as those with additional risk factors, existing heart disease, diabetes mellitus and metabolic syndrome.Although the latest clinical studies investigating combination therapies, i.e. dual therapy with both a statin and a fibrate, have demonstrated them to be effective for overall control of lipid parameters and reducing coronary events, it is not yet clear whether this offers any significant advantage over monotherapy. Results from ongoing longer-term end-point clinical studies may provide further information in this area and consequent reviews of primary care management policies for dyslipidemia. Statin monotherapy may be a reliable option for primary care treatment of dyslipidemia (including hypertriglyceridemia). |
|---|---|
| AbstractList | SUMMARYThe triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD.Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive subjects after increased low-density lipoprotein cholesterol (LDL-C), is defined by the National Cholesterol Education Programme (NCEP) as a fasting TG level of >2.26 mmol/l (>200 mg/dl) and is recognised as a primary indicator for treatment in type IIb dyslipidemia. Raised TG levels can be present in individuals at risk for CHD when the total cholesterol is normal. However, not all individuals with raised TG levels have increased risk of CHD. Factors such as: diet, age, lifestyle, and a range of medical conditions, drug therapy and metabolic disorders, can all affect the TG level. In some of these circumstances, other factors protect against the risk of CHD, and can minimise or negate the effect of the risk factors present.Although TG reducing therapy has been shown to be associated with an improved clinical outcome, more research is needed to determine whether this is an independent effect of TG reduction or an effect of normalising the overall lipid profile in hypertriglyceridemic patients. Further trials are required to quantify the clinical benefits of lowering TG to 'target' levels and to confirm targets defined by NCEP-II (shown in Table 1).The role of TG in CHD pathogenesis is thought to involve several direct and indirect mechanisms, such as effects on the metabolism of other lipoproteins, transport proteins, enzymes, and on coagulation and endothelial dysfunction. More research is required to fully elucidate the role of TG, the ways in which it can influence other risk factors and the mechanism of its own more direct role in the atherogenic process.Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. However, recent retrospective real-life clinical studies show that only 38% of patients receiving some form of lipid-lowering therapy achieved NCEP-defined LDL-C target levels, demonstrating the need for the use of more aggressive treatment.In hypertriglyceridemic patients, the newer statins, cerivastatin and atorvastatin, have shown comparable efficacy in reducing TG compared with the older statins. Achieving NCEP target lipid levels has been shown to reduce the risk of cardiovascular disease in dyslipidemic individuals, including high-risk patient groups such as those with additional risk factors, existing heart disease, diabetes mellitus and metabolic syndrome.Although the latest clinical studies investigating combination therapies, i.e. dual therapy with both a statin and a fibrate, have demonstrated them to be effective for overall control of lipid parameters and reducing coronary events, it is not yet clear whether this offers any significant advantage over monotherapy. Results from ongoing longer-term end-point clinical studies may provide further information in this area and consequent reviews of primary care management policies for dyslipidemia. Statin monotherapy may be a reliable option for primary care treatment of dyslipidemia (including hypertriglyceridemia). The triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD. Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive subjects after increased low-density lipoprotein cholesterol (LDL-C), is defined by the National Cholesterol Education Programme (NCEP) as a fasting TG level of >2.26 mmol/l (>200 mg/dl) and is recognised as a primary indicator for treatment in type IIb dyslipidemia. Raised TG levels can be present in individuals at risk for CHD when the total cholesterol is normal. However, not all individuals with raised TG levels have increased risk of CHD. Factors such as: diet, age, lifestyle, and a range of medical conditions, drug therapy and metabolic disorders, can all affect the TG level. In some of these circumstances, other factors protect against the risk of CHD, and can minimise or negate the effect of the risk factors present. Although TG reducing therapy has been shown to be associated with an improved clinical outcome, more research is needed to determine whether this is an independent effect of TG reduction or an effect of normalising the overall lipid profile in hypertriglyceridemic patients. Further trials are required to quantify the clinical benefits of lowering TG to 'target' levels and to confirm targets defined by NCEP-II (shown in Table 1). The role of TG in CHD pathogenesis is thought to involve several direct and indirect mechanisms, such as effects on the metabolism of other lipoproteins, transport proteins, enzymes, and on coagulation and endothelial dysfunction. More research is required to fully elucidate the role of TG, the ways in which it can influence other risk factors and the mechanism of its own more direct role in the atherogenic process. Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. However, recent retrospective real-life clinical studies show that only 38% of patients receiving some form of lipid-lowering therapy achieved NCEP-defined LDL-C target levels, demonstrating the need for the use of more aggressive treatment. In hypertriglyceridemic patients, the newer statins, cerivastatin and atorvastatin, have shown comparable efficacy in reducing TG compared with the older statins. Achieving NCEP target lipid levels has been shown to reduce the risk of cardiovascular disease in dyslipidemic individuals, including high-risk patient groups such as those with additional risk factors, existing heart disease, diabetes mellitus and metabolic syndrome. Although the latest clinical studies investigating combination therapies, i.e. dual therapy with both a statin and a fibrate, have demonstrated them to be effective for overall control of lipid parameters and reducing coronary events, it is not yet clear whether this offers any significant advantage over monotherapy. Results from ongoing longer-term end-point clinical studies may provide further information in this area and consequent reviews of primary care management policies for dyslipidemia. Statin monotherapy may be a reliable option for primary care treatment of dyslipidemia (including hypertriglyceridemia). The triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD. Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive subjects after increased low-density lipoprotein cholesterol (LDL-C), is defined by the National Cholesterol Education Programme (NCEP) as a fasting TG level of > 2.26 mmol/l (> 200 mg/dl) and is recognised as a primary indicator for treatment in type IIb dyslipidemia. Raised TG levels can be present in individuals at risk for CHD when the total cholesterol is normal. However, not all individuals with raised TG levels have increased risk of CHD. Factors such as: diet, age, lifestyle, and a range of medical conditions, drug therapy and metabolic disorders, can all affect the TG level. In some of these circumstances, other factors protect against the risk of CHD, and can minimise or negate the effect of the risk factors present. Although TG reducing therapy has been shown to be associated with an improved clinical outcome, more research is needed to determine whether this is an independent effect of TG reduction or an effect of normalising the overall lipid profile in hypertriglyceridemic patients. Further trials are required to quantify the clinical benefits of lowering TG to 'target' levels and to confirm targets defined by NCEP-II (shown in Table 1). The role of TG in CHD pathogenesis is thought to involve several direct and indirect mechanisms, such as effects on the metabolism of other lipoproteins, transport proteins, enzymes, and on coagulation and endothelial dysfunction. More research is required to fully elucidate the role of TG, the ways in which it can influence other risk factors and the mechanism of its own more direct role in the atherogenic process. Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. However, recent retrospective real-life clinical studies show that only 38% of patients receiving some form of lipid-lowering therapy achieved NCEP-defined LDL-C target levels, demonstrating the need for the use of more aggressive treatment. In hypertriglyceridemic patients, the newer statins, cerivastatin and atorvastatin, have shown comparable efficacy in reducing TG compared with the older statins. Achieving NCEP target lipid levels has been shown to reduce the risk of cardiovascular disease in dyslipidemic individuals, including high-risk patient groups such as those with additional risk factors, existing heart disease, diabetes mellitus and metabolic syndrome. Although the latest clinical studies investigating combination therapies, i.e. dual therapy with both a statin and a fibrate, have demonstrated them to be effective for overall control of lipid parameters and reducing coronary events, it is not yet clear whether this offers any significant advantage over monotherapy. Results from ongoing longer-term end-point clinical studies may provide further information in this area and consequent reviews of primary care management policies for dyslipidemia. Statin monotherapy may be a reliable option for primary care treatment of dyslipidemia (including hypertriglyceridemia). The triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD. Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive subjects after increased low-density lipoprotein cholesterol (LDL-C), is defined by the National Cholesterol Education Programme (NCEP) as a fasting TG level of > 2.26 mmol/l (> 200 mg/dl) and is recognised as a primary indicator for treatment in type IIb dyslipidemia. Raised TG levels can be present in individuals at risk for CHD when the total cholesterol is normal. However, not all individuals with raised TG levels have increased risk of CHD. Factors such as: diet, age, lifestyle, and a range of medical conditions, drug therapy and metabolic disorders, can all affect the TG level. In some of these circumstances, other factors protect against the risk of CHD, and can minimise or negate the effect of the risk factors present. Although TG reducing therapy has been shown to be associated with an improved clinical outcome, more research is needed to determine whether this is an independent effect of TG reduction or an effect of normalising the overall lipid profile in hypertriglyceridemic patients. Further trials are required to quantify the clinical benefits of lowering TG to 'target' levels and to confirm targets defined by NCEP-II (shown in Table 1). The role of TG in CHD pathogenesis is thought to involve several direct and indirect mechanisms, such as effects on the metabolism of other lipoproteins, transport proteins, enzymes, and on coagulation and endothelial dysfunction. More research is required to fully elucidate the role of TG, the ways in which it can influence other risk factors and the mechanism of its own more direct role in the atherogenic process. Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. However, recent retrospective real-life clinical studies show that only 38% of patients receiving some form of lipid-lowering therapy achieved NCEP-defined LDL-C target levels, demonstrating the need for the use of more aggressive treatment. In hypertriglyceridemic patients, the newer statins, cerivastatin and atorvastatin, have shown comparable efficacy in reducing TG compared with the older statins. Achieving NCEP target lipid levels has been shown to reduce the risk of cardiovascular disease in dyslipidemic individuals, including high-risk patient groups such as those with additional risk factors, existing heart disease, diabetes mellitus and metabolic syndrome. Although the latest clinical studies investigating combination therapies, i.e. dual therapy with both a statin and a fibrate, have demonstrated them to be effective for overall control of lipid parameters and reducing coronary events, it is not yet clear whether this offers any significant advantage over monotherapy. Results from ongoing longer-term end-point clinical studies may provide further information in this area and consequent reviews of primary care management policies for dyslipidemia. Statin monotherapy may be a reliable option for primary care treatment of dyslipidemia (including hypertriglyceridemia).The triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is strongly associated with an increased risk of CHD. Hypertriglyceridemia, the second most common dyslipidemic abnormality in hypertensive subjects after increased low-density lipoprotein cholesterol (LDL-C), is defined by the National Cholesterol Education Programme (NCEP) as a fasting TG level of > 2.26 mmol/l (> 200 mg/dl) and is recognised as a primary indicator for treatment in type IIb dyslipidemia. Raised TG levels can be present in individuals at risk for CHD when the total cholesterol is normal. However, not all individuals with raised TG levels have increased risk of CHD. Factors such as: diet, age, lifestyle, and a range of medical conditions, drug therapy and metabolic disorders, can all affect the TG level. In some of these circumstances, other factors protect against the risk of CHD, and can minimise or negate the effect of the risk factors present. Although TG reducing therapy has been shown to be associated with an improved clinical outcome, more research is needed to determine whether this is an independent effect of TG reduction or an effect of normalising the overall lipid profile in hypertriglyceridemic patients. Further trials are required to quantify the clinical benefits of lowering TG to 'target' levels and to confirm targets defined by NCEP-II (shown in Table 1). The role of TG in CHD pathogenesis is thought to involve several direct and indirect mechanisms, such as effects on the metabolism of other lipoproteins, transport proteins, enzymes, and on coagulation and endothelial dysfunction. More research is required to fully elucidate the role of TG, the ways in which it can influence other risk factors and the mechanism of its own more direct role in the atherogenic process. Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. However, recent retrospective real-life clinical studies show that only 38% of patients receiving some form of lipid-lowering therapy achieved NCEP-defined LDL-C target levels, demonstrating the need for the use of more aggressive treatment. In hypertriglyceridemic patients, the newer statins, cerivastatin and atorvastatin, have shown comparable efficacy in reducing TG compared with the older statins. Achieving NCEP target lipid levels has been shown to reduce the risk of cardiovascular disease in dyslipidemic individuals, including high-risk patient groups such as those with additional risk factors, existing heart disease, diabetes mellitus and metabolic syndrome. Although the latest clinical studies investigating combination therapies, i.e. dual therapy with both a statin and a fibrate, have demonstrated them to be effective for overall control of lipid parameters and reducing coronary events, it is not yet clear whether this offers any significant advantage over monotherapy. Results from ongoing longer-term end-point clinical studies may provide further information in this area and consequent reviews of primary care management policies for dyslipidemia. Statin monotherapy may be a reliable option for primary care treatment of dyslipidemia (including hypertriglyceridemia). |
| Author | Breuer, Hans-Willi M. |
| Author_xml | – sequence: 1 givenname: Hans-Willi M. surname: Breuer fullname: Breuer, Hans-Willi M. email: breuer.carolus@gmx.de organization: Abteilung für Innere Medizin, St. Carolus-Krankenhaus Görlitz, Carolusstr. 212, 02827 Görlitz, Germany |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1131821$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11464448$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1rGzEQhkVJaZy0956KKKW3baWVdqV1T8E0TSEQKOlZyNpRo6CVXEl28L-vjJ1-GNKTQPM8w8w7Z-gkxAAIvabkA6Wy-0gYIWIYCBsoFaSVz9CMcsEaLoU4QbNduan17hSd5XxPCG3lMLxAp5TynnMuZ0hfbVeQSnI__NZAciNMTs_xBf4GGwcPOFq88C44o3398rDRwQDWYcS3CXSZIBR8syouhjzHl9GsM44BL2qnjc5FFxdeoudW-wyvDu85-n75-XZx1VzffPm6uLhuDOuH0lBODOk5GVjX9R1tGQBplyNvW0PFKG3d11oJYKC1nIIYqbbSLDmxVFg59uwcvd_3XaX4cw25qMllA97rAHGdlaCEdaQfKvj2CLyP6xTqbKqtaQpCJanQmwO0Xk4wqlVyk05b9ZhcBd4dAJ1rODbVYFz-i2NUtrRi_R4zKeacwCrjdrHEUJJ2XlGidpdUx5esIjkSf7d-Wvm0V1ywMU36ISY_qqK3PqbH-dh_7Pk_9h1oX-6MTvAnnyflX6Lwwjk |
| CODEN | CMROCX |
| CitedBy_id | crossref_primary_10_1038_ja_2005_88 crossref_primary_10_1016_j_atherosclerosis_2007_12_026 crossref_primary_10_1016_j_atherosclerosis_2013_12_053 crossref_primary_10_1016_S0025_7753_02_73379_4 crossref_primary_10_1111_bdi_12240 crossref_primary_10_1016_j_compbiomed_2014_12_005 crossref_primary_10_1016_S0021_9150_03_00136_9 crossref_primary_10_1016_j_vph_2004_05_002 crossref_primary_10_1016_S8756_3282_02_00803_7 crossref_primary_10_1038_oby_2009_337 crossref_primary_10_3109_0886022X_2011_577545 crossref_primary_10_1016_j_foodchem_2012_09_017 crossref_primary_10_1039_c2fo30235g crossref_primary_10_1371_journal_pone_0180687 crossref_primary_10_1016_j_freeradbiomed_2011_03_041 crossref_primary_10_1161_ATVBAHA_107_148429 crossref_primary_10_1007_s00216_014_8255_0 |
| Cites_doi | 10.1177/147323000002800201 10.1001/jama.282.21.2051 10.1161/01.CIR.99.6.779 10.1111/j.0954-6820.1988.tb15891.x 10.1016/1047-2797(92)90033-M 10.1016/S0026-0495(99)90009-4 10.1001/jama.1990.03450210059033 10.1016/0002-8703(86)90296-6 10.1046/j.1365-2796.2000.00724.x 10.1056/NEJM199511163332001 10.1161/01.CIR.101.24.2777 10.1161/01.CIR.102.2.179 10.1067/mhj.2000.108001 10.1016/S0026-0495(00)91169-7 10.1056/NEJM199908053410604 10.1016/S0002-9149(00)01012-2 10.1016/S0735-1097(99)00351-4 10.1016/S0022-2275(20)33505-7 10.1016/S0021-9150(99)00055-6 10.1001/jama.1993.03500040071040 10.1097/00005344-200003000-00003 10.1016/S0021-9150(00)00379-8 10.1097/00041433-200008000-00006 10.1001/jama.1993.03500230097036 10.1016/0002-9149(93)90905-R 10.1016/S0167-5273(99)00108-4 10.1161/01.CIR.97.18.1876 10.1097/00043798-199604000-00014 10.1067/mhj.2000.108508 10.1161/01.CIR.102.2.e16 10.1016/S0002-9149(98)00035-6 10.2337/diacare.21.1.160 10.1001/archinte.160.4.459 10.1016/S0735-1097(98)00083-7 10.1001/jama.1985.03350400082026 10.1016/S0015-0282(00)01601-0 10.1056/NEJM199610033351401 10.1001/archinte.1992.00400130054004 10.1161/01.CIR.100.5.475 10.1007/s002280050663 10.2337/diab.45.3.S27 10.1001/archinte.1997.00440300051004 10.1001/jama.1988.03410130125037 10.1016/S1053-2498(00)00128-5 10.1161/01.CIR.85.1.37 10.1016/S0021-9150(99)00190-2 |
| ContentType | Journal Article |
| Copyright | 2001 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2001 2001 INIST-CNRS Copyright Librapharm 2001 |
| Copyright_xml | – notice: 2001 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2001 – notice: 2001 INIST-CNRS – notice: Copyright Librapharm 2001 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88I 8AF 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M1P M2P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U S0X 7X8 |
| DOI | 10.1185/0300799039117028 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health Medical collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Central Student MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-4877 |
| EndPage | 73 |
| ExternalDocumentID | 76650949 11464448 1131821 10_1185_0300799039117028 11171462 |
| Genre | Research Article Journal Article Review |
| GroupedDBID | --- .55 .GJ 00X 03L 08R 0BK 0R~ 29F 34G 39C 3V. 4.4 53G 5GY 5RE 6J9 6PF 7X7 88E 88I 8AF 8AO 8FI 8FJ 8R4 8R5 AAJNR AALIY AALUX AAMIU AAPUL AAPXX AAQRR AAUGY AAWTL ABBAB ABBKH ABEIZ ABIVO ABLJU ABLKL ABOCM ABPTK ABUPF ABUWG ABWCV ABZEW ACENM ACFUF ACGFO ACGFS ACGOD ACKZS ACLSK ADBBV ADCVX ADFCX ADFOM ADFZZ ADRBQ AECIN AEIIZ AENEX AEOZL AEYQI AFKRA AFLEI AFWLO AGDLA AGFJD AGRBW AGYJP AHMBA AIJEM AIRBT AJVHN AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AMDAE AZQEC BABNJ BENPR BLEHA BOHLJ BPHCQ BRMBE BVXVI CAG CCCUG COF CS3 CYYVM CZDIS DKSSO DRXRE DU5 DWQXO DWTOO EBS EJD F5P FYUFA GNUQQ H13 HCIFZ HZ~ IPNFZ J5H JENTW KRBQP KSSTO KWAYT KYCEM L7B LJTGL M1P M2P M2Q M44 M4Z O9- P2P PQEST PQQKQ PQUKI PROAC PSQYO Q2X QQXMO RIG RNANH RVRKI RWL S0X SJN TAE TFDNU TFL TFW UEQFS UKHRP V1S X7M ZGI ~1N ABJNI ABLIJ ABXYU ACIEZ ALIPV ALYBC CCPQU HMCUK TBQAZ TDBHL TERGH TUROJ AAGDL AAORF AAYXX ABWVI ACOPL ACYZI ADYSH AFRVT AMPGV CITATION EMOBN NUSFT PHGZM PHGZT IQODW PJZUB PPXIY TASJS CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c369t-140c0640935565123ee02bd422c17d8f118ff8eece2f41e7d1af8cb40f17f8d63 |
| IEDL.DBID | 7X7 |
| ISSN | 0300-7995 |
| IngestDate | Fri Sep 05 04:46:42 EDT 2025 Fri Jul 25 03:19:15 EDT 2025 Wed Feb 19 01:27:20 EST 2025 Mon Jul 21 09:14:23 EDT 2025 Tue Jul 01 04:26:50 EDT 2025 Thu Apr 24 23:06:45 EDT 2025 Wed Dec 25 09:02:38 EST 2024 Wed Jun 21 08:14:56 EDT 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Human Enzyme Pathogenesis Enzyme inhibitor Cardiovascular disease Metabolic diseases Lipids Hyperlipoproteinemia Statin derivative Review Triglyceride Enzymopathy Coronary heart disease Cerivastatin Chemotherapy Treatment Hypertriglyceridemia Risk factor Hydroxymethylglutaryl-CoA reductase Oxidoreductases Dyslipemia Antilipemic agent |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c369t-140c0640935565123ee02bd422c17d8f118ff8eece2f41e7d1af8cb40f17f8d63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PMID | 11464448 |
| PQID | 207970180 |
| PQPubID | 48040 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_71035069 pascalfrancis_primary_1131821 informaworld_taylorfrancis_310_1185_0300799039117028 proquest_journals_207970180 crossref_citationtrail_10_1185_0300799039117028 informahealthcare_journals_10_1185_0300799039117028 pubmed_primary_11464448 crossref_primary_10_1185_0300799039117028 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20010000 1/1/2001 2001-01-00 2001 2001-00-00 20010101 |
| PublicationDateYYYYMMDD | 2001-01-01 |
| PublicationDate_xml | – year: 2001 text: 20010000 |
| PublicationDecade | 2000 |
| PublicationPlace | Reading |
| PublicationPlace_xml | – name: Reading – name: England – name: Newbury |
| PublicationTitle | Current medical research and opinion |
| PublicationTitleAlternate | Curr Med Res Opin |
| PublicationYear | 2001 |
| Publisher | Informa UK Ltd Taylor & Francis Librapharm Informa Healthcare |
| Publisher_xml | – name: Informa UK Ltd – name: Taylor & Francis – name: Librapharm – name: Informa Healthcare |
| References | Assmann G (CIT0003) 1998; 19 Ma P (CIT0030) 2000; 7 Fontborme A (CIT0051) 1988; 12 CIT0071 A desktop guide to type I (CIT0018) 1999; 16 CIT0074 CIT0073 CIT0031 McLaughlin T (CIT0054) 2000; 85 CIT0075 CIT0034 CIT0033 CIT0077 CIT0070 Haskell WL (CIT0076) 1994; 89 Tavazzi L (CIT0012) 1998; 19 Miller M. (CIT0002) 1999; 22 Morey SS (CIT0014) 2000; 61 CIT0036 CIT0079 Guidelines for the diagnosis of heart failure (CIT0011) 1995; 16 CIT0037 CIT0039 Funke Cullen P (CIT0050) 1998; 19 CIT0085 CIT0040 CIT0087 Chait A (CIT0059) 1980; 10 CIT0045 Pederson TR (CIT0069) 1998; 97 CIT0088 Goldbourt U (CIT0072) 1998; 19 A desktop guide to type (CIT0019) 1999; 16 CIT0080 Naoumova RP (CIT0062) 1998; 1394 Despres JP (CIT0048) 2000; 102 Fukadome Kato J (CIT0066) 1996; 35 Holman RR (CIT0083) 1999; 48 Pyorala K (CIT0016) 1994; 110 CIT0046 CIT0005 CIT0049 CIT0004 CIT0007 CIT0006 CIT0009 CIT0008 Mack WJ (CIT0081) 1996; 16 CIT0010 Fontbonne A (CIT0084) 1987; 13 CIT0053 CIT0056 Schachter M (CIT0043) 2000; 7 CIT0055 Brown BG (CIT0082) 2000 CIT0058 CIT0013 Poulter N (CIT0044) 2000; 7 CIT0017 Stampfer MJ (CIT0022) 1991; 325 Rader DJ (CIT0026) 2000; 84 CIT0061 Whitman SC (CIT0027) 1997; 17 CIT0060 Sanders E (CIT0038) 2000; 92 CIT0063 CIT0021 CIT0065 CIT0064 CIT0067 Miller M. (CIT0001) 1998; 19 Kirchrnair R (CIT0086) 1999; 149 Fontbonne A (CIT0052) 1989; 32 Karpe F (CIT0057) 1998; 48 Jeppesen J (CIT0023) 1998; 97 CIT0025 CIT0024 CIT0068 Whitman SC (CIT0028) 1999; 40 CIT0029 |
| References_xml | – ident: CIT0031 doi: 10.1177/147323000002800201 – ident: CIT0008 doi: 10.1001/jama.282.21.2051 – ident: CIT0077 doi: 10.1161/01.CIR.99.6.779 – volume: 92 start-page: 319 year: 2000 ident: CIT0038 publication-title: J Natl Med Assoc – ident: CIT0075 doi: 10.1111/j.0954-6820.1988.tb15891.x – ident: CIT0005 doi: 10.1016/1047-2797(92)90033-M – volume: 10 start-page: 17 year: 1980 ident: CIT0059 publication-title: Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest – volume: 85 start-page: 3085 year: 2000 ident: CIT0054 publication-title: Carbohydrate-induced hypertrig-lyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Met – volume: 19 start-page: M8 year: 1998 ident: CIT0003 publication-title: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J – ident: CIT0040 doi: 10.1016/S0026-0495(99)90009-4 – volume: 102 start-page: 11 year: 2000 ident: CIT0048 publication-title: Is the total cholesterol/HDL cholesterol ratio a better cumulative index of `dysmetabolism' and of coronary heart disease risk than the LDL cholesterol/HDL cholesterol ratio? Circulation – volume: 22 start-page: 111 year: 1999 ident: CIT0002 publication-title: Clin Cardiol – volume: 17 start-page: 1707 year: 1997 ident: CIT0027 publication-title: Uptake of type III hypertriglyceridemic VLDL-C by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol – volume: 61 start-page: 2534 year: 2000 ident: CIT0014 publication-title: Am Fam Phys – ident: CIT0080 doi: 10.1001/jama.1990.03450210059033 – volume: 1394 start-page: 146 year: 1998 ident: CIT0062 publication-title: Cholesterol synthesis is increased in mixed hyperlipidaemia. Biochem Biophys Acta – ident: CIT0004 doi: 10.1016/0002-8703(86)90296-6 – volume: 19 start-page: L33 year: 1998 ident: CIT0012 publication-title: Eur J Heart – volume: 16 start-page: 716 year: 1999 ident: CIT0019 publication-title: European Diabetes Policy Group – ident: CIT0007 doi: 10.1046/j.1365-2796.2000.00724.x – ident: CIT0067 doi: 10.1056/NEJM199511163332001 – ident: CIT0055 doi: 10.1161/01.CIR.101.24.2777 – ident: CIT0063 doi: 10.1161/01.CIR.102.2.179 – year: 2000 ident: CIT0082 publication-title: et al – volume: 97 start-page: 1029 year: 1998 ident: CIT0023 publication-title: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation – ident: CIT0045 doi: 10.1067/mhj.2000.108001 – ident: CIT0034 doi: 10.1016/S0026-0495(00)91169-7 – volume: 48 start-page: A1 588 issue: 1 year: 1999 ident: CIT0083 publication-title: Diabetes – ident: CIT0074 doi: 10.1056/NEJM199908053410604 – volume: 110 start-page: 121 year: 1994 ident: CIT0016 publication-title: Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis – volume: 35 start-page: 337 year: 1996 ident: CIT0066 publication-title: Hyperlipidemia associated with multiple myeloma. Intern Med – ident: CIT0036 doi: 10.1016/S0002-9149(00)01012-2 – ident: CIT0013 doi: 10.1016/S0735-1097(99)00351-4 – volume: 97 start-page: 1453 year: 1998 ident: CIT0069 publication-title: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation – volume: 40 start-page: 1017 year: 1999 ident: CIT0028 publication-title: J Lipid Res doi: 10.1016/S0022-2275(20)33505-7 – ident: CIT0024 doi: 10.1016/S0021-9150(99)00055-6 – ident: CIT0009 doi: 10.1001/jama.1993.03500040071040 – volume: 19 start-page: H18 year: 1998 ident: CIT0001 publication-title: Eur Heart J – volume: 7 start-page: 613 year: 2000 ident: CIT0043 publication-title: Brit J Cardiol – ident: CIT0037 doi: 10.1097/00005344-200003000-00003 – ident: CIT0039 doi: 10.1016/S0021-9150(00)00379-8 – volume: 7 start-page: 186 year: 2000 ident: CIT0044 publication-title: Br J Cardiol – volume: 12 start-page: 557 year: 1988 ident: CIT0051 publication-title: The Paris Prospective Study. Int J Obes – ident: CIT0061 doi: 10.1097/00041433-200008000-00006 – volume: 149 start-page: 139 year: 1999 ident: CIT0086 publication-title: Statins in diabetic dyslipidemia. Wien Med Wochenschr – ident: CIT0010 doi: 10.1001/jama.1993.03500230097036 – volume: 32 start-page: 300 year: 1989 ident: CIT0052 publication-title: West – volume: 16 start-page: 697 year: 1996 ident: CIT0081 publication-title: Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol – volume: 84 start-page: 43 year: 2000 ident: CIT0026 publication-title: Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation. Med Clin North Am – volume: 19 start-page: H42 year: 1998 ident: CIT0072 publication-title: Eur Heart J – volume: 13 start-page: 350 year: 1987 ident: CIT0084 publication-title: Diabet Metab – ident: CIT0071 doi: 10.1016/0002-9149(93)90905-R – ident: CIT0088 doi: 10.1016/S0167-5273(99)00108-4 – ident: CIT0017 doi: 10.1161/01.CIR.97.18.1876 – volume: 19 start-page: C5 year: 1998 ident: CIT0050 publication-title: Lipoproteins and cardiovascular risk - from genetics to CHD prevention. Eur Heart J – volume: 325 start-page: 373 year: 1991 ident: CIT0022 publication-title: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Engl J Med – volume: 7 start-page: 780 year: 2000 ident: CIT0030 publication-title: 4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidaemia. Brit J Cardiol – ident: CIT0046 doi: 10.1097/00043798-199604000-00014 – ident: CIT0060 doi: 10.1067/mhj.2000.108508 – ident: CIT0056 doi: 10.1161/01.CIR.102.2.e16 – ident: CIT0070 doi: 10.1016/S0002-9149(98)00035-6 – ident: CIT0085 doi: 10.2337/diacare.21.1.160 – volume: 48 start-page: 301 year: 1998 ident: CIT0057 publication-title: Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotryglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Metabolism – ident: CIT0087 doi: 10.1001/archinte.160.4.459 – ident: CIT0021 doi: 10.1016/S0735-1097(98)00083-7 – ident: CIT0079 doi: 10.1001/jama.1985.03350400082026 – ident: CIT0064 doi: 10.1016/S0015-0282(00)01601-0 – ident: CIT0068 doi: 10.1056/NEJM199610033351401 – ident: CIT0006 doi: 10.1001/archinte.1992.00400130054004 – ident: CIT0073 doi: 10.1161/01.CIR.100.5.475 – ident: CIT0033 doi: 10.1007/s002280050663 – ident: CIT0065 doi: 10.2337/diab.45.3.S27 – ident: CIT0053 doi: 10.1001/archinte.1997.00440300051004 – ident: CIT0049 doi: 10.1001/jama.1988.03410130125037 – volume: 89 start-page: 975 year: 1994 ident: CIT0076 publication-title: The Stanford Coronary Risk Intervention Project (S CRIP) . Circulation – ident: CIT0029 doi: 10.1016/S1053-2498(00)00128-5 – volume: 16 start-page: 253 year: 1999 ident: CIT0018 publication-title: European Diabetes Policy Group – volume: 16 start-page: 741 year: 1995 ident: CIT0011 publication-title: Eur Heart J – ident: CIT0058 doi: 10.1161/01.CIR.85.1.37 – ident: CIT0025 doi: 10.1016/S0021-9150(99)00190-2 |
| SSID | ssj0012899 |
| Score | 1.7384359 |
| SecondaryResourceType | review_article |
| Snippet | SUMMARYThe triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level... The triglyceride (TG) level is one of several lipid parameters that can aid prediction of coronary heart disease (CHD) risk. An elevated plasma TG level is... |
| SourceID | proquest pubmed pascalfrancis crossref informaworld informahealthcare |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 60 |
| SubjectTerms | 3-Hydroxy-3-methlyglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor Atherogenesis Atorvastatin Atorvastatin Calcium Biological and medical sciences Cerivastatin Coronary Disease - blood Coronary Disease - etiology Coronary Disease - prevention & control Coronary heart disease Drug Therapy, Combination Dyslipidemia Fibrate Gemfibrozil - therapeutic use General and cellular metabolism. Vitamins Heptanoic Acids - therapeutic use High-density lipoprotein cholesterol (HDL-C) Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypertriglyceridemia Hypertriglyceridemia - blood Hypertriglyceridemia - complications Hypertriglyceridemia - diet therapy Hypertriglyceridemia - drug therapy Hypolipidemic Agents - therapeutic use Lipid Low-density lipoprotein cholesterol (LDL-C) Medical sciences Niacin - therapeutic use Pharmacology. Drug treatments Pyridines - therapeutic use Pyrroles - therapeutic use Risk Factors Statin Triglyceride Triglycerides - blood Very low-density lipoprotein cholesterol (VLDL-C) |
| Title | Hypertriglyceridemia: A Review of Clinical Relevance and Treatment Options: Focus on Cerivastatin |
| URI | https://www.tandfonline.com/doi/abs/10.1185/0300799039117028 https://www.ncbi.nlm.nih.gov/pubmed/11464448 https://www.proquest.com/docview/207970180 https://www.proquest.com/docview/71035069 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7aBEovJX3GSZPq0EsPJpYl23IuJS1ZlkJDKQ3szch60EKw09hb6L_PjC0725Qs-CRLwtaMpBnNp28A3uOmkHrNVWxMomLp0U_RvixjVyfC11ZY7wa2z4t8eSm_rLJVwOZ0AVY5rYnDQm1bQ2fkdBJSFsQ29fH6d0xJoyi4GjJoPIZdjoYIZW4oVrO_xcmXGIMISUy8Z1OUUmUnVIZFRI_Oi4RSsW_sSnuBs_TnjMC6x2NKAErd4Rj6MfnFw9bpsEst9uBZMC_Z2agPz-GRa17Ak68hgP4S9BL9zpsef-zqr0HlI2y8PmVnbLzCwlrPpruSjNKpDAABphvLZkQ6a0cczClbtGbdsbZh1NMfTXeTfjWv4HJx_uPzMg5ZFmIj8rKP0cMyFM4jovUct3_hXJLWVqap4YVVHsfLe-WccamX3BWWa69MLRPPC69sLl7DTtM2bh9YobhPRW49yl9qK1HemUmcy7GiFyaJ4GQa5coECnLKhHFVDa6Iyqr7congw9zieqTf2FJX_Ce4KszIbksruSnaqh8OSoJgK_Fws6N_VODu6ziukimP4HBSibtvmHU4gnfzW5zOFKPRjWvXXYUGn8iSvIzgzahHGx1LtF2lOtja8yE8HVFy9LyFnf5m7Y7QbOrr42FyHMPup_OLb99vAbV5Ez0 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcUHmVUEp9gAOHqHk4ibdShQp0taXtCqFW6i04fgikKilNFtQfx39jJnHSpah7q5STY1uWZzye8cx8A_AGL4XIylD4SgXC5xbtFGnHY98UQWwLHWtrWrTPWTo95Z_PkrMV-NPnwlBYZS8TW0GtK0Vv5PQSMs4Iber9xU-fikaRc7WvoCFdZQW92yKMubyOQ3P1Gy24evfgE5L7bRRN9k8-Tn1XZMBXcTpufDQwFHmzCGc8xdsvNiaICs2jSIWZFhYVcGuFMcpElocm06G0QhU8sGFmhU5jnPcerHJ6PxnB6of92ZevgxuDrJnOjRH4hLzW-0lFsk1t2EQA7WEWUDH4hXtxzaGmfh9iwG4gqVIIp6yRirYrv3G7ftzek5M1eOQUXLbXceRjWDHlE7h_7Fz4T0FO0fK9bHBrz68Usj9F58sdtse6JBpWWdZnazIq6NKGKDBZajbExLOqi8TZYZNKzWtWlYxm-iUpO-pH-QxO74QEz2FUVqV5ASwToY3iVFvkQC41R45LVGBMih1trAIPtvtdzpUDQadaHOd5awyJJL9JFw_eDSMuOgCQJX3j_wiXO5lQLxnFF0mbN-1TjSNsHt8-bPMfFrheXYhyOgo92OhZ4noNwynyYGv4iwKFvESyNNW8zlHljJMgHXuw3vHRwsQctWcuXi6deQseTE-Oj_Kjg9nhBjzsYvboewWj5nJuNlGJa4rX7qgw-HbXp_MvBQVU3w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dS9xAEB-sgvSl2O9orfvQPvQhXJLNx0aQYqvHWdtDSgXf0s1-0IIkau5a_BP7X3Um2cSrxXsT8pRkl5D53pn5DcAbNAqRlaHwlQqEH1uMU6TNc9-UAbel5tqaFu1zmk5O409nydkK_Ol7YaissteJraLWtaIzcjoJyTNCmxpZVxVxcjB-f3Hp0wApSrT20zSkm7Kg91q0MdfjcWyuf2M01-wdHSDp30bR-PDbx4nvBg74iqf5zMdgQ1FmizDHU7SE3JggKnUcRSrMtLDojFsrjFEmsnFoMh1KK1QZBzbMrNApx30fwFqGRh_jwLUPh9OTr0NKgyKbLqUR-ITC1udMRTKie3iLwNrDLKDB8As2csMhqP4Y6sFuoapSOadskKK2G8Vxt6_c2szxBjxyzi7b77jzMayY6gmsf3Hp_KcgJxgFX83w155fKxQFqtSXu2yfdQ01rLas79xkNNylLVdgstJsqI9ndVeVs8vGtZo3rK4Y7fRLUqfUz-oZnN4LCZ7DalVX5iWwTIQ24qm2yI2x1DFyX6ICY1J80XIVeDDq_3KhHCA6zeU4L9rASCTFbbp48G5YcdGBgSx5l_9HuMLph2bJqniRtMWsPbZxhC343cu2_2GBm68LUWdHoQdbPUvcfMMgUR7sDE9RuVDGSFamnjcFup88CdLcgxcdHy1sHKMnHYvNpTvvwDpKafH5aHq8BQ-78j26XsHq7GputtGfm5WvnaQw-H7fwvkXZ6RZIw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypertriglyceridemia%3A+A+review+of+clinical+relevance+and+treatment+options%3A+Focus+on+cerivastatin&rft.jtitle=Current+medical+research+and+opinion&rft.au=BREUER%2C+Hans-Willi+M&rft.date=2001&rft.pub=Librapharm&rft.issn=0300-7995&rft.volume=17&rft.issue=1&rft.spage=60&rft.epage=73&rft_id=info:doi/10.1185%2F0300799039117028&rft.externalDBID=n%2Fa&rft.externalDocID=1131821 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-7995&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-7995&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-7995&client=summon |